Neogene Therapeutics

Neogene Therapeutics, Inc. is a pre-clinical stage biotechnology company pioneering the development of next-generation, fully personalized engineered T cells therapies for a broad spectrum of cancers.

The Company’s engineered T cells target mutated proteins found in cancer cells due to cancer-associated DNA mutations, or neo-antigens, that render tumor cells vulnerable to detection by T cells. Neogene’s proprietary technology platform aims to identify TCR genes with specificity for neo-antigens from tumor biopsies. Neogene’s novel approach intends to deliver a tailored set of TCR genes for each individual patient, which will be engineered into patient-derived T cells directing them towards neo-antigens in tumor cells, with the goal of providing a fully personalized engineered T cell therapy for cancer.